Evoke Pharma Cmn (EVOK) 8.38 $EVOK
Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
GlobeNewswire - Wed Jun 01, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that the last subject completed treatment in its pivotal Phase 3 study for EVK-001, the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The primary endpoint in the four-week, U.S. multicenter, randomized, double-blind, placebo-controlled clinical trial is the change in gastroparesis symptoms at week 4 utilizing a proprietary Patient Report Outcome (PRO) symptom assessment instrument. The Company expects to report top-line Phase 3 study results early in the third quarter of 2016.
EVOK: 8.38 (+1.36)
Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016
GlobeNewswire - Tue May 24, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from its successful thorough electrocardiogram (ECG) study of EVK-001, its patented nasal delivery formulation of metoclopramide for the treatment of symptoms associated with acute and recurrent diabetic gastroparesis in women, were presented at Digestive Disease Week (DDW) 2016.
EVOK: 8.38 (+1.36)
Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001
GlobeNewswire - Thu May 19, 6:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has signed an exclusive commercial supply agreement with COSMA S.p.A. for the active pharmaceutical ingredient (API) in its product candidate EVK-001. EVK-001 is the Company's novel nasal spray for delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women.
EVOK: 8.38 (+1.36)
Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 7:00AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the first quarter 2016 on Wednesday, May 11, 2016, after the close of the market.
EVOK: 8.38 (+1.36)
Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001
GlobeNewswire - Tue May 03, 6:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK) today announced that it expects to provide top line data results from its pivotal Phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis early in the third quarter of 2016. The study was designed to enroll approximately 200 subjects and the Company has confirmed that 205 subjects have now been randomized in the trial. EVK-001 is the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 8.38 (+1.36)
Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
GlobeNewswire - Mon Apr 25, 7:01AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has successfully completed patient enrollment in its pivotal Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 8.38 (+1.36)
Evoke Pharma Reports Fourth Quarter and Year End 2015 Results
GlobeNewswire - Thu Mar 10, 3:05PM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2015.
EVOK: 8.38 (+1.36)
Gastroparesis Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts - Key Vendors: GlaxoSmithKline, Evoke Pharma, Ocera Therapeutics - Research and Markets
BusinessWire - Mon Mar 07, 12:04PM CST
Research and Markets (http://www.researchandmarkets.com/research/6bxkgx/gastroparesis) has announced the addition of the "Gastroparesis Global Clinical Trials Review, H2, 2015" report to their offering.
EVOK: 8.38 (+1.36), OCRX: 2.61 (+0.08), GSK: 43.38 (+0.04)
Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Year End 2015 Financial Results
GlobeNewswire - Fri Mar 04, 7:30AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the fourth quarter and full year 2015 on Thursday, March 10, 2016, after the close of the market.
EVOK: 8.38 (+1.36)
Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts
GlobeNewswire - Thu Mar 03, 7:41AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has engaged Regulatory Professionals, Inc. (RPI) to provide additional personnel and expertise to the Company in connection with the preparation and submission of its New Drug Application (NDA) for metoclopramide nasal spray (EVK-001) to the U.S. Food and Drug Administration (FDA).
EVOK: 8.38 (+1.36)
What's Next for KaloBios as Shkreli Faces Fraud Charges?
Arpita Dutt - Zacks Investment Research - Fri Dec 18, 1:55PM CST
KaloBios' (KBIO) shares slumped more than 50% in pre-market trading following the arrest of CEO Martin Shkreli.
EVOK: 8.38 (+1.36), MYL: 44.54 (+0.84), AMPH: 16.80 (+0.14)
Did the Wu-Tang Clan Rat Out Martin Shkreli to SEC?
David Bartosiak - Zacks Investment Research - Thu Dec 17, 3:47PM CST
Notorious Biopharma CEO Martin Shkreli finds out the hard way that the SEC ain’t nothing to mess with.
EVOK: 8.38 (+1.36), RTRX: 18.65 (+0.35), MYL: 44.54 (+0.84), AMPH: 16.80 (+0.14)
Evoke Pharma Reports Third Quarter 2015 Results
GlobeNewswire - Thu Nov 12, 3:10PM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2015.
EVOK: 8.38 (+1.36)
Evoke to Participate in the Brean Capital 2015 Life Sciences Summit
GlobeNewswire - Tue Nov 10, 7:30AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, R.Ph., President and CEO will be participating in the Brean Capital 2015 Life Sciences Summit on Monday, November 16, 2015 at the Millennium Broadway Hotel in New York City.
EVOK: 8.38 (+1.36)
Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 05, 7:30AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of the market.
EVOK: 8.38 (+1.36)
Diabetic Gastroparesis - Pipeline Review, H2 2015
M2 - Fri Oct 23, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7t58rx/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Cempra, Inc. - Evoke Pharma, Inc. - GlaxoSmithKline Plc - Ironwood Pharmaceuticals, Inc. - Rhythm Pharmaceuticals - Shire Plc For more information visit http://www.researchandmarkets.com/research/7t58rx/diabetic
EVOK: 8.38 (+1.36), IRWD: 13.37 (+0.25), SHPG: 188.21 (-1.31), GSK: 43.38 (+0.04), CEMP: 17.98 (+0.17)
Evoke Pharma Strengthens Financial Position
GlobeNewswire - Wed Oct 07, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the amendment of its loan and security agreement with Square 1 Bank (the "credit facility"
to extend the interest-only payment term for an additional 12 months. Furthermore, through cash management and At-The-Market equity placements under its agreement with MLV & Co. LLC, Evoke had an estimated $10.7 million in cash as of September 30, 2015, an increase of $0.8 million from June 30, 2015. The Company now projects that its current cash resources should be sufficient to fund operations through October 2016.
EVOK: 8.38 (+1.36)
Evoke fulfils 75% patient enrollment in Phase 3 clinical trial under credit agreemnt
M2 - Tue Sep 29, 6:02AM CDT
Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) said on Monday that it has reached a key milestone under its USD4.5m loan, security and credit agreement with Square 1 Bank.
EVOK: 8.38 (+1.36)
Evoke Reaches Study Enrollment Milestone Associated With Credit Facility
GlobeNewswire - Mon Sep 28, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company has reached a key milestone under its $4.5 million loan and security agreement (the credit facility) with Square 1 Bank (Square 1). As of today, the Company has enrolled 150 patients in its current Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 8.38 (+1.36)
U.S. Food and Drug Administration's (FDA) Draft Guidance is Consistent With Evoke's Current Phase 3 Study Design and Endpoint for EVK-001
GlobeNewswire - Tue Sep 15, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its Phase 3 clinical trial design for EVK-001 (metoclopramide nasal spray) is consistent with the FDA's recommendations in the recently released draft guidance entitled Gastroparesis: Clinical Evaluation of Drugs for Treatment - Guidance for Industry (Draft Guidance). The new Draft Guidance contains the FDA's current thinking on trial design and study endpoints for drug development in the treatment of gastroparesis.
EVOK: 8.38 (+1.36)
Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
GlobeNewswire - Wed Jun 01, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that the last subject completed treatment in its pivotal Phase 3 study for EVK-001, the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The primary endpoint in the four-week, U.S. multicenter, randomized, double-blind, placebo-controlled clinical trial is the change in gastroparesis symptoms at week 4 utilizing a proprietary Patient Report Outcome (PRO) symptom assessment instrument. The Company expects to report top-line Phase 3 study results early in the third quarter of 2016.
EVOK: 8.38 (+1.36)
Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016
GlobeNewswire - Tue May 24, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from its successful thorough electrocardiogram (ECG) study of EVK-001, its patented nasal delivery formulation of metoclopramide for the treatment of symptoms associated with acute and recurrent diabetic gastroparesis in women, were presented at Digestive Disease Week (DDW) 2016.
EVOK: 8.38 (+1.36)
Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001
GlobeNewswire - Thu May 19, 6:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has signed an exclusive commercial supply agreement with COSMA S.p.A. for the active pharmaceutical ingredient (API) in its product candidate EVK-001. EVK-001 is the Company's novel nasal spray for delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women.
EVOK: 8.38 (+1.36)
Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 7:00AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the first quarter 2016 on Wednesday, May 11, 2016, after the close of the market.
EVOK: 8.38 (+1.36)
Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001
GlobeNewswire - Tue May 03, 6:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK) today announced that it expects to provide top line data results from its pivotal Phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis early in the third quarter of 2016. The study was designed to enroll approximately 200 subjects and the Company has confirmed that 205 subjects have now been randomized in the trial. EVK-001 is the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 8.38 (+1.36)
Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
GlobeNewswire - Mon Apr 25, 7:01AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has successfully completed patient enrollment in its pivotal Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 8.38 (+1.36)
Evoke Pharma Reports Fourth Quarter and Year End 2015 Results
GlobeNewswire - Thu Mar 10, 3:05PM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2015.
EVOK: 8.38 (+1.36)
Gastroparesis Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts - Key Vendors: GlaxoSmithKline, Evoke Pharma, Ocera Therapeutics - Research and Markets
BusinessWire - Mon Mar 07, 12:04PM CST
Research and Markets (http://www.researchandmarkets.com/research/6bxkgx/gastroparesis) has announced the addition of the "Gastroparesis Global Clinical Trials Review, H2, 2015" report to their offering.
EVOK: 8.38 (+1.36), OCRX: 2.61 (+0.08), GSK: 43.38 (+0.04)
Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Year End 2015 Financial Results
GlobeNewswire - Fri Mar 04, 7:30AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the fourth quarter and full year 2015 on Thursday, March 10, 2016, after the close of the market.
EVOK: 8.38 (+1.36)
Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts
GlobeNewswire - Thu Mar 03, 7:41AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has engaged Regulatory Professionals, Inc. (RPI) to provide additional personnel and expertise to the Company in connection with the preparation and submission of its New Drug Application (NDA) for metoclopramide nasal spray (EVK-001) to the U.S. Food and Drug Administration (FDA).
EVOK: 8.38 (+1.36)
What's Next for KaloBios as Shkreli Faces Fraud Charges?
Arpita Dutt - Zacks Investment Research - Fri Dec 18, 1:55PM CST
KaloBios' (KBIO) shares slumped more than 50% in pre-market trading following the arrest of CEO Martin Shkreli.
EVOK: 8.38 (+1.36), MYL: 44.54 (+0.84), AMPH: 16.80 (+0.14)
Did the Wu-Tang Clan Rat Out Martin Shkreli to SEC?
David Bartosiak - Zacks Investment Research - Thu Dec 17, 3:47PM CST
Notorious Biopharma CEO Martin Shkreli finds out the hard way that the SEC ain’t nothing to mess with.
EVOK: 8.38 (+1.36), RTRX: 18.65 (+0.35), MYL: 44.54 (+0.84), AMPH: 16.80 (+0.14)
Evoke Pharma Reports Third Quarter 2015 Results
GlobeNewswire - Thu Nov 12, 3:10PM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2015.
EVOK: 8.38 (+1.36)
Evoke to Participate in the Brean Capital 2015 Life Sciences Summit
GlobeNewswire - Tue Nov 10, 7:30AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, R.Ph., President and CEO will be participating in the Brean Capital 2015 Life Sciences Summit on Monday, November 16, 2015 at the Millennium Broadway Hotel in New York City.
EVOK: 8.38 (+1.36)
Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 05, 7:30AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of the market.
EVOK: 8.38 (+1.36)
Diabetic Gastroparesis - Pipeline Review, H2 2015
M2 - Fri Oct 23, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7t58rx/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Cempra, Inc. - Evoke Pharma, Inc. - GlaxoSmithKline Plc - Ironwood Pharmaceuticals, Inc. - Rhythm Pharmaceuticals - Shire Plc For more information visit http://www.researchandmarkets.com/research/7t58rx/diabetic
EVOK: 8.38 (+1.36), IRWD: 13.37 (+0.25), SHPG: 188.21 (-1.31), GSK: 43.38 (+0.04), CEMP: 17.98 (+0.17)
Evoke Pharma Strengthens Financial Position
GlobeNewswire - Wed Oct 07, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the amendment of its loan and security agreement with Square 1 Bank (the "credit facility"
to extend the interest-only payment term for an additional 12 months. Furthermore, through cash management and At-The-Market equity placements under its agreement with MLV & Co. LLC, Evoke had an estimated $10.7 million in cash as of September 30, 2015, an increase of $0.8 million from June 30, 2015. The Company now projects that its current cash resources should be sufficient to fund operations through October 2016. EVOK: 8.38 (+1.36)
Evoke fulfils 75% patient enrollment in Phase 3 clinical trial under credit agreemnt
M2 - Tue Sep 29, 6:02AM CDT
Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) said on Monday that it has reached a key milestone under its USD4.5m loan, security and credit agreement with Square 1 Bank.
EVOK: 8.38 (+1.36)
Evoke Reaches Study Enrollment Milestone Associated With Credit Facility
GlobeNewswire - Mon Sep 28, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company has reached a key milestone under its $4.5 million loan and security agreement (the credit facility) with Square 1 Bank (Square 1). As of today, the Company has enrolled 150 patients in its current Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 8.38 (+1.36)
U.S. Food and Drug Administration's (FDA) Draft Guidance is Consistent With Evoke's Current Phase 3 Study Design and Endpoint for EVK-001
GlobeNewswire - Tue Sep 15, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its Phase 3 clinical trial design for EVK-001 (metoclopramide nasal spray) is consistent with the FDA's recommendations in the recently released draft guidance entitled Gastroparesis: Clinical Evaluation of Drugs for Treatment - Guidance for Industry (Draft Guidance). The new Draft Guidance contains the FDA's current thinking on trial design and study endpoints for drug development in the treatment of gastroparesis.
EVOK: 8.38 (+1.36)
